Cartesian Therapeutics Inc.
09/26/2024 | Press release | Distributed by Public on 09/26/2024 05:03
Material Event Form 8 K
Item 8.01 Other Events.
On September 20, 2024, Cartesian Therapeutics, Inc. (the "Company") held its previously announced Special Meeting of Stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the Company approved the issuance of shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), upon conversion of the Company's Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series B Preferred Stock").
The Automatic Conversion (as defined in the Certificate of Designation) of the Series B Preferred Stock occurred on September 25, 2024 at 5:00 p.m. Eastern Time pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the "Certificate of Designation"), of the Series B Preferred Stock. Following the Automatic Conversion of the Series B Preferred Stock, there are 23,893,525 shares of the Company's Common Stock issued and outstanding.